VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, announced its launch today. Vilya is co-founded by world-class scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D., and ARCH Venture Partners

* A team of scientists at Institute of Protein Design led by David Baker, Ph.D., and ARCH Venture Partners launch Vilya to create a new transformational class of medicines
* Paper published today in Cell describes the ground-breaking research behind Vilya's foundational technology leveraging advanced computational approaches to design novel molecules, never before found in nature, with atomic-level accuracy and drug-like properties.
* $50 million Series A financing led by ARCH Venture Partners